BlackRock, Inc. ownership in LGDN / Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated

DE ˙ DB ˙ US53220K5048

198,00 € ↑2,00 (1,02%)

2026-06-04
PREZZO DELLE AZIONI

Security	DE:LGDN / Ligand Pharmaceuticals Incorporated
Institution	BlackRock, Inc.
Latest Disclosed Ownership	2,839,251 shares
Ownership	14.50%

2025-10-17 - BlackRock, Inc. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,839,251 shares of Ligand Pharmaceuticals Incorporated (DE:LGDN). This represents 14.5 percent ownership of the company. In their previous filing dated 2025-02-05 , BlackRock, Inc. had reported owning 2,945,939 shares, indicating a decrease of -3.62 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2025-10-17	2025-10-17	13G/A	2,945,939	2,839,251	-3.62	14.50	-7.05
2025-02-05	2025-02-05	13G/A	2,962,094	2,945,939	-0.55	15.60	-8.24
2024-01-22	2024-01-22	13G/A	2,789,479	2,962,094	6.19	17.00	3.03
2023-01-26	2023-01-26	13G/A	2,789,479	2,789,479	0.00	16.50	0.00
2023-01-20	2023-01-20	13G/A	2,742,808	2,789,479	1.70	16.50	0.61
2022-01-27	2022-01-27	13G/A	2,742,808	2,742,808	0.00	16.40	0.00
2022-01-25	2022-01-25	13G/A	1,965,996	2,742,808	39.51	16.40	34.43
2021-01-27	2021-01-27	13G/A	1,965,996	1,965,996	0.00	12.20	0.00
2021-01-27	2021-01-27	13G/A	2,385,158	1,965,996	-17.57	12.20	-10.29
2020-02-10	2020-02-10	13G/A	2,761,861	2,385,158	-13.64	13.60	4.62
2019-02-11	2019-02-11	13G/A	2,996,960	2,761,861	-7.84	13.00	-8.45
2018-01-19	2018-01-19	13G/A	2,430,096	2,996,960	23.33	14.20	22.41
2017-01-12	2017-01-12	13G/A	2,120,927	2,430,096	14.58	11.60	13.73
2016-07-08	2016-07-08	13G/A	1,958,105	2,120,927	8.32	10.20	4.08
2016-01-26	2016-01-26	13G/A		1,958,105		9.80
2015-01-09	2015-01-09	13G/A		2,025,768		10.30
2014-11-07	2014-11-07	13G/A		2,070,484		10.30
2014-01-31	2014-01-31	13G/A		1,972,467		9.70
2013-02-11	2013-02-11	13G/A		1,183,015		5.93
2012-02-09	2012-02-09	13G		1,182,106		6.01

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-13	2026-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,961,923	21,692	0.74	591,348	6.37	0.0008
2026-02-12	2025-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,940,231	55,704	1.93	555,909	8.80	0.0094
2025-11-12	2025-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,884,527	-29,214	-1.00	510,965	54.26	0.0089
2025-08-12	2025-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,913,741	-6,494	-0.22	331,234	7.88	0.0063
2025-05-02	2025-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,920,235	-25,849	-0.88	307,034	-2.74	0.0064
2025-02-07	2024-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,946,084	-53,548	-1.79	315,673	5.14	0.0064
2024-11-13	2024-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,999,632	128,136	4.46	300,233	24.09	0.0063
2024-08-13	2024-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,871,496	3,226	0.11	241,952	15.40	0.0055
2024-05-10	2024-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,868,270	-94,044	-3.17	209,671	-0.90	0.0049
2024-02-13	2023-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,962,314	121,230	4.27	211,568	24.28	0.0054
2023-11-13	2023-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,841,084	-65,075	-2.24	170,238	-18.75	0.0049
2023-08-11	2023-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,906,159	67,497	2.38	209,534	0.35	0.0058
2023-05-12	2023-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,838,662	48,898	1.75	208,812	12.05	0.0062
2023-02-13	2022-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,789,764	124,146	4.66	186,356	-18.81	0.0058
2022-11-14	2022-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,665,618	-39,229	-1.45	229,538	-4.88	0.0078
2022-08-12	2022-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,704,847	-28,460	-1.04	241,323	-21.51	0.0077
2022-05-12	2022-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,733,307	-9,501	-0.35	307,469	-27.42	0.0083
2022-02-10	2021-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,742,808	11,614	0.43	423,655	11.34	0.0108
2021-11-09	2021-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,731,194	686,816	33.60	380,512	41.88	0.0107
2021-08-11	2021-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,044,378	-82,005	-3.86	268,200	-17.26	0.0075
2021-05-07	2021-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,126,383	160,387	8.16	324,166	65.80	0.0095
2021-02-05	2020-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,965,996	-170,114	-7.96	195,519	-3.98	0.0062
2020-11-06	2020-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,136,110	8,455	0.40	203,614	-14.44	0.0075
2020-08-14	2020-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,127,655	-80,881	-3.66	237,978	48.18	0.0095
2020-05-01	2020-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,208,536	-176,622	-7.41	160,605	-35.43	0.0079
2020-02-13	2019-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,385,158	-73,748	-3.00	248,749	1.63	0.0095
2019-11-08	2019-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,458,906	-39,999	-1.60	244,759	-14.19	0.0103
2019-08-22	2019-06-30	13F/A-1	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,498,905	-240,350	-8.77	285,250	-17.16	0.0122
2019-08-13	2019-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,498,905	-240,350		285,250
2019-05-09	2019-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,739,255	-22,606	-0.82	344,350	-8.12	0.0154
2019-02-08	2018-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,761,861	-584,545	-17.47	374,785	-59.20	0.0189
2018-11-09	2018-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	3,346,406	81,432	2.49	918,554	35.80	0.0397
2018-08-09	2018-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	3,264,974	251,145	8.33	676,405	35.89	0.0312
2018-05-09	2018-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	3,013,829	16,869	0.56	497,763	21.29	0.0238
2018-02-09	2017-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,996,960	51,259	1.74	410,374	2.32	0.0195
2017-11-14	2017-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,945,701	261,821	9.76	401,058	23.09	0.0202
2017-08-10	2017-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,683,880	68,887	2.63	325,822	17.72	0.0173
2017-05-12	2017-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,614,993	2,613,424	166,566.22	276,770	173,969.18	0.0152
2017-02-10	2016-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,569	-359	-18.62	159	-19.29	0.0002
2016-11-08	2016-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,928	-2,872	-59.83	197	-65.56	0.0003
2016-08-10	2016-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	4,800	3,419	247.57	572	289.12	0.0009
2016-05-10	2016-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,381	860	165.07	147	162.50	0.0002
2016-02-11	2015-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	521	-159	-23.38	56	-5.08	0.0001
2015-11-13	2015-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	680	-5,991	-89.81	59	-91.23	0.0001
2015-08-07	2015-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	6,671	5,993	883.92	673	1,194.23	0.0010
2015-05-13	2015-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	678	-658	-49.25	52	-26.76	0.0001
2015-02-09	2014-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,336	790	144.69	71	173.08	0.0001
2014-10-29	2014-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	546	0	0.00	26	-23.53	0.0000
2014-08-06	2014-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	546	-83	-13.20	34	-20.93	0.0001
2014-05-02	2014-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	629	190	43.28	43	86.96	0.0001
2014-02-12	2013-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	439	-29	-6.20	23	15.00	0.0000
2013-11-12	2013-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	468	0	0.00	20	11.11	0.0000
2013-08-13	2013-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	468	468		18		0.0000

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.